Our laboratory has experience with the synthesis of antibodies against the cancer-specific antigen B7-H3 and their coupling with 124I—in this setup, the imaging agent (the radioactive iodide, detected with PET) is also the therapeutic one, with isotope decay being the main method of injury to cancer cells [83]. Here, CD276 is linked to cancer.